ReproCELL Incorporated (TYO:4978)

Market Cap	14.30B
Revenue (ttm)	2.72B
Net Income (ttm)	-110.00M
Shares Out	94.70M
EPS (ttm)	-1.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,123,800
Average Volume	2,308,885
Open	144.00
Previous Close	145.00
Day's Range	144.00 - 170.00
52-Week Range	97.00 - 277.00
Beta	0.79
RSI	53.73
Earnings Date	May 14, 2025

About ReproCELL

ReproCELL Incorporated provides stem cell research and drug discovery services in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, pluripotent stem cells, and synfire induced neurons; 3D cell culture; and labware. The company also provides research stem cell, genomics, clinica...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 96
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4978

Financial Performance

In 2023, ReproCELL's revenue was 2.43 billion, a decrease of -17.85% compared to the previous year's 2.95 billion. Losses were -31.00 million, -89.84% less than in 2022.